Document is current
Any future updates will be listed below
-
Authors
Mayoh, Chelsea
Gifford, Andrew J.
Terry, Rachael
Lau, Loretta M. S.
Wong, Marie
Rao, Padmashree
Shai-Hee, Tyler
Saletta, Federica
Khuong-Quang, Dong-Anh
Qin, Vicky
Mateos, Marion K.
Meyran, Deborah
Miller, Katherine E.
Yuksel, Aysen
Mould, Emily V. A.
Bowen-James, Rachel
Govender, Dinisha
Senapati, Akanksha
Zhukova, Nataliya
Omer, Natacha
Dholaria, Hetal
Alvaro, Frank
Tapp, Heather
Diamond, Yonatan
Pozza, Luciano Dalla
Moore, Andrew S.
Nicholls, Wayne
Gottardo, Nicholas G.
McCowage, Geoffrey
Hansford, Jordan R.
Khaw, Seong-Lin
Wood, Paul J.
Catchpoole, Daniel
Cottrell, Catherine E.
Mardis, Elaine R.
Marshall, Glenn M.
Tyrrell, Vanessa
Haber, Michelle
Ziegler, David S.
Vittorio, Orazio
Trapani, Joseph A.
Cowley, Mark J.
Neeson, Paul J.
Ekert, Paul G. https://orcid.org/0000-0002-2976-8617
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council
Kids Cancer Alliance
Tour de cure
Australian Lions Children's Cancer Research Foundation
Steven Walter children's cancer foundation
Cure Brain Cancer Foundation
Kids' Cancer Project
Luminesce Alliance
Cancer Institute NSW
- License Information
-
More Information
Article History
Received: 13 October 2022
Accepted: 8 March 2023
First Online: 3 April 2023
Declarations
:
: Each patient provided written informed consent as part of the Australian ZERO Childhood Cancer Precision Medicine programme upon enrolment into either the TARGET pilot programme or the PRISM clinical trial. Ethics for TARGET was approved by the Sydney Children’s Hospitals Network Human Research Ethics Committee (LNR/14/SCH/497). Ethics for PRISM was approved by the Hunter New England Human Research Ethics Committee of the Hunter New England Local Health District (reference no. 17/02/015/4.06) and the New South Wales Human Research Ethics Committee (reference no. HREC/17/HNE/29). The research conformed to the principles of the Helsinki Declaration.
: Not applicable.
: P.G.E receives an annual payment related to the Walter and Eliza Hall Institute distribution of royalties scheme. P.G.E. consults for Illumina. P.J.N. receives research funding from BMS, Roche Genentech, Allergan, Compugen, Merck Sharpe Dohme and Crispr therapeutics. J.R.H. declares honorarium or Bayer and Alexion Pharmaceuticals; Boxer Capital unrelated to this work. The remaining authors declare that they have no competing interests.
